The emergence and spread of multidrug-resistant bacteria are global concerns. Overcoming antibiotic resistance is an urgent and imperative issue. A major hurdle in the elimination of pathogens in a host is the poor uptake of many antibiotics by infected host cells, which results in intracellular persistence of bacteria and failure of antimicrobial therapy [1] [2] [3] . Vibrio vulnificus, a halophilic Gram-negative bacillus, is a highly virulent, opportunistic pathogen that causes gastroenteritis, primary sepsis, and wound infection in humans. Infection by V. vulnificus commonly occurs via ingestion of contaminated seafood and an exposed open wound, and its incidence is significantly rising 4 . V. vulnificus spreads rapidly and causes extensive tissue damage, leading to a mortality rate of over 50% among infected patients with sepsis 5
The emergence and spread of multidrug-resistant bacteria are global concerns. Overcoming antibiotic resistance is an urgent and imperative issue. A major hurdle in the elimination of pathogens in a host is the poor uptake of many antibiotics by infected host cells, which results in intracellular persistence of bacteria and failure of antimicrobial therapy [1] [2] [3] . Vibrio vulnificus, a halophilic Gram-negative bacillus, is a highly virulent, opportunistic pathogen that causes gastroenteritis, primary sepsis, and wound infection in humans. Infection by V. vulnificus commonly occurs via ingestion of contaminated seafood and an exposed open wound, and its incidence is significantly rising 4 . V. vulnificus spreads rapidly and causes extensive tissue damage, leading to a mortality rate of over 50% among infected patients with sepsis 5 . V. vulnificus infects a host via gastrointestinal tract 6 , and disrupts tight junctions of intestinal cells, leading to its intracellular colonization in the intestine intestinal epithelium 7 . Combinational antibiotics therapy is the most common treatment regimen against V. vulnificus infection 8, 9 . However, resistance to antibiotics and inefficient delivery of antibiotics contribute to the high fatality rate observed following V. vulnificus infection 2, 4, 9, 10 . Therefore, innovative approaches for developing alternative antibacterial agents are in demand. Diverse classes of antibacterial compounds have been designed for effective treatment of fatal bacterial infections. Among them, antimicrobial peptides (AMPs), which are a crucial part of the host defense system with broad-spectrum antimicrobial activity, are prospective drug candidates 11, 12 . Complex mechanisms of action of AMPs decrease the potential for emergence of AMP-resistant pathogens 13 . HP (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , a 19-amino-acid peptide (AKKVFKRLEKLFSKIQNDK) derived from the N-terminus of Helicobacter pylori ribosomal protein L1 (RpL1), shows broad-spectrum antimicrobial activity against bacteria, fungi, and protozoa without causing hemolysis 14, 15 . HPA3P, a derivative of HP (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) with substitutions of E9P, Q16W, and D18W, exhibits antimicrobial activity against Escherichia coli, Staphylococcus aureus, Pseudomonas Aeruginosa, Bacillus subtilis, and Salmonella typhimurium via membrane penetration 16 . The instability of peptides in vivo and low penetrability in host cells are the major limiting factors for the clinical application of AMPs 17 . To overcome these limitations, we developed an AMP delivery system using gold nanoparticle-DNA aptamer (AuNP-Apt) conjugate. AuNPs have low-toxicity and non-immnogenicity 18, 19 , and our previous studies indicate that the AuNP-Apt conjugates efficiently deliver proteins and peptides, maintaining their intact structure and function, into diverse types of cells [20] [21] [22] . In addition, the elimination of intracellular Salmonella enterica serovar Typhimurium in host cells by AuNP-Apt-conjugated AMP has been demonstrated 21 .
In the present study, we investigated the effectiveness of a Helicobacter pylori-derived AMP, HPA3P, delivered by AuNP-Apt against V. vulnificus infection, which involved mechanisms of infection and virulence different from those of S. typhimurium. We found that the in vivo delivery of HPA3P loaded on AuNP-Apt effectively inhibited V. vulnificus, leading to 100% survival rate among V. vulnificus-infected mice.
Results

Preparation of hexahistidine-tagged HPA3P (HPA3P
His ) and antimicrobial mechanism of HPA3P His against V. vulnificus. Three different AMPs, HPA3P, HPA3P2, and A3-APO, were tested for their bactericidal activities against V. vulnificus, S. typhimurium, or S. aureus by measuring their minimal inhibitory concentrations (MICs) and minimal bactericidal activity (MBC). Among them, HPA3P exhibited the lowest MIC and MBC for V. vulnificus and showed similar or variable MICs and MBCs for other gram-negative or -positive bacteria (Table 1) . For The C-terminal end of HPA3P was tagged with hexahistidine (His) to load HPA3P on the AuNP-Apt His conjugate by interaction of His aptamer (Apt His ) with His-tagged HPA3P (HPA3P His ). This His-tagging to HPA3P did not alter the MIC and MBC against V. vulnificus (Table 1) , and AuNP-Apt His itself exhibited no bactericidal activity up to 10 nM. The antibacterial activity of these AMPs was attributable to their bactericidal activity rather than their bacteriostatic property as indicated by similar MIC and MBC levels for three bacterial species tested in this study (Table 1) . When compared with the MIC and MBC of antibiotics for V. vulnificus, the antibacterial activity of HPA3P
His was more potent than ampicillin and weaker than doxycycline and erythromycin (Table 1) .
The structural features of HPA3P His in an aqueous solution of Dulbecco's phosphate-buffered solution (DPBS), 30 mM sodium dodecyl sulfate (SDS), or 50% 2,2,2-trifluoroethanol (TFE) were studied using circular dichroism (CD). SDS can form micelles with a negatively charged surface and, thereby, mimic bacterial membranes, and TFE can induce a helical structure and stabilize secondary structures 23 . HPA3P His exhibits as random coils in aqueous DPBS solution (Fig. 1A) . By contrast, HPA3P
His showed an α-helical structure in solutions containing either SDS or TFE (Fig. 1A) . These CD results suggest that HPA3P
His is capable to bind to bacterial membranes due to its electrostatic and hydrophobic interactions, imposing structural change of the membranes. Next, the ability of HPA3P
His to permeabilize intact membranes was analyzed using the membrane potential-sensitive dye 3,3′-dipropylthiadicarbocyanine iodide (DiSC 3 -5). Should antimicrobial peptides or any other compounds affect the potential of the bacterial membrane, the dye releases into the buffer, resulting increase in fluorescence 24 . Once the fluorescence intensity stabilized, V. vulnificus MO6-24/0 were treated with HPA3P
His at 0.25X, 0.5X, and 1X of the MIC. Treatment with HPA3P His resulted in an immediate increase in fluorescence in a concentration-dependent manner, suggesting that HPA3P
His has membrane-depolarizing activity (Fig. 1B) . We also examined whether the integrity of the bacterial membrane was disrupted by HPA3P His , using SYTOX Green and propidium iodide (PI). These dyes cannot pass through intact membranes, but will bind to DNA upon membrane damage by antimicrobial agents, resulting in an increase in fluorescence. The fluorescence intensity of SYTOX Green increased after treatment with HPA3P His , indicating the bacterial membrane was disrupted (Fig. 1C) . We further confirmed the disruption of V. vulnificus membranes integrity by PI staining and flow cytometry. As shown in Fig. 1D, 21 .22% of the bacteria in the V. vulnificus MO6-24/0 control group stained positive for PI. The groups treated with HPA3P
His showed the increased PI fluorescent signal in a concentration-dependent manner compared to the control (Fig. 1D) . Collectively, these data indicate that HPA3P
His induces bacterial cell death through a membranolytic mechanism. His -HPA3P His -treated cells decreased by 90% in 10 min (Fig. 3A) . In contrast, only 20% or 40% decrease in viable V. vulnificus cells after for 10 or 30 min of treatment with HPA3P
Effective delivery of HPA3P
His was observed, respectively (Fig. 3A) . HPA3P His and AuNP-Apt His -HPA3P His did not exhibit cytotoxicity against HeLa cells and mouse erythrocytes up to 10 µM as determined by cell viability and hemolysis assays, respectively ( Fig. 3B and C His were dead at 4 h after infection (Fig. 3D) . In contrast, the treatment of infected HeLa cells with AuNP-Apt His -HPA3P His completely prevented their death (Fig. 3D) . Thus, 
Prevention of death of V. vulnificus-infected mice by AuNP-Apt
His -HPA3P His treatment. We extended our study to test the effectiveness of AuNP-Apt His -HPA3P His in vivo in mice. To induce septicemia and wound infection caused by the invasion of V. vulnificus into tissues and vasculature, V. vulnificus was subcutaneously inoculated into the skin of mice 27 . The spreading of V. vulnificus in the organs of mice, including spleen, inguinal lymph node, and liver, was monitored for 4 h after inoculation. As shown in Fig. 4A , V. vulnificus sufficiently colonized in these organs as early as 30 min. Using this mouse model, the in vivo therapeutic effect of AuNP-Apt His -HPA3P His was examined. Mice were infected with V. vulnificus, followed by a single intravenous injection with buffer, AuNP-Apt His , HPA3P His , or AuNP-Apt His -HPA3P His at 2 h after inoculation. Then, the survival rate of the mice was observed for 120 h. All infected mice injected with buffer, AuNP-Apt His , or HPA3P
His died before 42 h after infection (Fig. 4B) . In sharp contrast, all the infected mice injected with AuNP-Apt His -HPA3P His survived until 120 h (Fig. 4B) . To ensure that the survival of mice was due to the inhibition of V. vulnificus by HPA3P
His delivered by AuNP-Apt His , the number of viable V. vulnificus cells was measured in the spleen, inguinal lymph node, and liver homogenates of these mice at 18 h after inoculation. There was no His showed significant colonization of V. vulnificus (Fig. 4C) .
Discussion
In this study, we demonstrated that AuNP-Apt His -HPA3P His is a potent antimicrobial agent against V. vulnificus infection, supported by its rapid and highly effective bactericidal action in host cells. V. vulnificus is a representative pathogenic strain that evades the host defense systems and replicates rapidly, resulting in mortality among humans and aquatic animals. Its infection contributes to 95% of seafood-related mortality in humans 9, 28 . A high dose of combinational antibiotics, such as doxycycline + ceftazidime, is a common primary therapeutic regimen against V. vulnificus infection 29 . However, studies on antibiotic sensitivity of V. vulnificus isolates from the US, Europe, and Asia indicate that substantial portions of the isolates show resistance to various antibiotics 9 . This emergence of multidrug-resistant V. vulnificus imposes the need to seek alternative therapeutic approaches.
Naturally occurring AMPs are produced as gene-encoded precursor proteins by all living organisms from prokaryotes to humans to protect the host from infections and inhibit competing microbes in bacteria 11 . The interaction of amphipathic AMPs with bacterial membrane disrupts the integrity of the membrane, leading to rapid membrane permeabilization and lysis of bacteria 30, 31 . Structural and functional diversities of AMPs along with their rapid mode of action render AMPs attractive pharmacological agents that could overcome antibiotic resistance. Few AMPs are already in the market and various AMPs are currently under clinical trial as antimicrobial agents 11, 12 . However, the currently used AMPs are largely limited to topical applications due to their rapid proteolytic degradation and clearance as peptides in addition to their ineffective in vivo systemic delivery 11, 32 . Although researchers have mainly focused on identifying bactericidal AMPs and their derivatives in the last decade, limited efforts have been made for innovative development to enhance the effectiveness of AMPs in living systems. AMPs, being cationic or amphiphilic, can readily bind to serum proteins and are degraded by proteolytic enzymes in the blood plasma, followed by rapid clearance from circulation, resulting in loss of their antimicrobial activity [32] [33] [34] . To prevent AMP proteolysis, elaborative chemical modifications of AMPs, such as generation of prodrug, cyclization of AMPs, and tagging or blocking of amino-or carboxyl ends of AMPs, have been attempted [35] [36] [37] [38] . More recently, various AMP formulations with nanocarriers, such as lipids and polymers, were evaluated to increase the efficacy of AMPs; however, usually the process of loading AMPs is complex and their in vivo effectiveness was minimal or not confirmed 12, 32 . Currently, only a few reports on the development of bactericidal AMPs against V. vulnificus infection are available [39] [40] [41] [42] [43] . To the best of our knowledge, we are the first to develop an AMP-derived antibacterial agent with high efficacy in V. vulnificus-infected mammal. A single intravenous (IV) injection of AuNP-Apt His -HPA3P His in V. vulnificus-infected mice efficiently and rapidly eliminates V. vulnificus in the host, as evidenced by no viable V. vulnificus in the organs of mice at 18 h after injection (Fig. 4C) . All the infected mice survived after the administration of AuNP-Apt His -HPA3P His , which was in sharp contrast to 0% survival rate among control mice (Fig. 4B) . The intravenous injection of HPA3P
His alone failed to prevent death of V. vulnificus-infected mice, resulting in 100% mortality (Fig. 4B) . These results indicate that this robust bactericidal activity observed is mainly attributable to the conjugation of HPA3P
His to AuNP-Apt
His
. The functional contribution of AuNP-Apt His is that it enables the efficient intracellular delivery of HPA3P His to the host in addition to the increase in stability of HPA3P
His by protecting HPA3P His from proteolysis 21 . Another advantageous property of this system lies in its simplicity to be employed in a wide range of applications, where AuNP-Apt His conjugates can load any type of AMPs after His-tagging by simple mixing for few minutes at room temperature. Moreover, AuNP-Apt His conjugates were effective after a single administration, and thus, this longer lasting efficacy is a useful parameter that can help in avoiding short-term repetitive administration and reducing overall cost for therapy. Additionally, AuNP-Apt His -HPA3P His did not exhibit any evident host toxicity (Figs 3B,C and 4B). Their efficient intracellular uptake and effective bactericidal activity would contribute to reduced dosing regimen, which renders minimizing possible toxic response. Earlier studies reported that AuNPs exhibit little toxicity, which is largely dependent on the particle size 44, 45 . 15-nm AuNPs used in this study have known to be non-cytotoxic 20, 46, 47 . Thus, these advantageous properties of AuNP-Apt His -derived AMP delivery system render it a promising antibacterial therapeutic candidate. To facilitate the development of AuNP-aptamer-AMP conjugate-based therapeutics, pre-clinical studies that prove the safety of AuNP-aptamer composites as well as the assessment of economic feasibility for large-scale production of AMPs are necessary. In addition, massive bactericidal screening of other candidate AMPs using HPA3P
His as a reference would contribute to development of more effective AuNP-aptamer-AMPs as antimicrobial therapeutics.
Methods
Peptide synthesis and purification. The peptides were synthesized using the 9-fluorenylmethoxycarbonyl (Fmoc) solid-phase method on Rink amide 4-methyl benzhydrylamine resin (Novabiochem; 0.55 mmol/g) with a Liberty microwave peptide synthesizer (CEM Co., Matthews, NC, USA). The peptides were prepared according to a previously described method 48 . In brief, serial two-fold dilutions of 0.5-64 μM of each AMP were added to the CA-MHB media containing cultures of mid-log phase bacteria (5 × 10 5 CFUs/ml). The cultures were grown for an additional 16-24 h at 37 °C. After incubation, MIC and MBC were determined as the lowest concentrations of AMP inhibiting bacterial growth based on the OD 600 measurements or required to kill 99.9% of the test inoculum, respectively.
SCientifiC REPORTS | 7: 13572 | DOI:10.1038/s41598-017-14127-z Circular dichroism (CD) spectroscopy. CD spectroscopy was performed using a Jasco-810 spectrapolarimeter (Jasco, Tokyo, Japan), with a quartz cell with a 1.0-mm path length. Spectra were measured at wavelengths ranging from 190 to 250 nm. CD spectral data of the peptide at a fixed concentration of 40 µΜ were recorded in Dulbecco's phosphate-buffered solution (DPBS), 30 mM sodium dodecyl sulfate (SDS) solution, or 50% 2,2,2-trifluoroethanol (TFE) solution.
Membrane depolarization assay. The effect of HPA3P
His on bacterial membrane depolarization was measured using the membrane potential-sensitive dye DiSC 3 -5. V. vulnificus MO6-24/0 was cultured in LBS medium at 30 °C and then washed three times with buffer A (DPBS containing 20 mM glucose). The bacteria were resuspended to an OD 600 of 0.05 in buffer A with 0.1 M KCl added and then DiSC 3 -5 was added to a final concentration of 0.1 µΜ. This mixture was incubated for 15 min to stabilize the level of fluorescence. Different concentrations, 0.25X, 0.5X, and 1X of the MIC of HPA3P
His and DPBS were added. The fluorescence was continuously measured for 10 min at an excitation wavelength of 622 nm and emission wavelength of 670 nm.
SYTOX Green uptake assay. V. vulnificus MO6-24/0 were grown in LBS medium at 30 °C, washed, and then resuspended in DPBS to 2 × 10 7 CFU/ml. After adding 1 µΜ SYTOX Green, the bacteria were incubated for 15 min in the dark. HPA3P
His was added at 0.25X, 0.5X, and 1X of the MIC to the bacterial suspensions. Changes in fluorescence as a result of the interactions between SYTOX Green and bacterial DNA were measured at an excitation wavelength of 485 nm and emission wavelength of 520 nm.
Flow cytometric analysis of bacterial membrane disruption. The disruption of V. vulnificus membranes by the peptide was analyzed by flow cytometry. V. vulnificus MO6-24/0 were cultured in LBS medium and harvested by centrifugation at 6000 g for 10 min. After washing with DPBS, the bacteria were resuspended to an OD 600 of 0.2, and then treated with 0.5X, 1X, or 2X of the MIC of HPA3P
His and DPBS for 5 min at 30 °C with shaking at 140 rpm. After the treatment, the bacteria were harvested and incubated with 10 μg/ml of PI for 20 min. Bacterial cell staining with PI was measured using a CytoFLEX flow cytometer (Beckman, Brea, CA, USA).
Preparation of AuNP-Apt conjugates and AuNP-Apt-AMP complex. Citrate-stabilized AuNPs (15 nm diameter) were purchased from BBI Life Science (UK). His-tag DNA aptamers 20 were conjugated to AuNPs by a previously described method 49 and the AuNP-Apt-AMP complex was prepared according to a previously described procedure 21 . The size and ζ-potential of AuNP-Apt-AMP were investigated using a dynamic light scattering spectrophotometer (ELSZ-1000; Otsuka Electronic Korea, Seongnam, Korea).
Binding capacity assay. Binding capacity assay between AMPs and AuNP-Apt conjugates was performed according to a previously described method 20 .
Mammalian cell culture. HeLa cells were cultured in DMEM (Welgene, Daegu, Korea) supplemented with 10% fetal bovine serum (Welgene) and 1% penicillin-streptomycin (Welgene) at 37 °C/5% CO 2 . Cytotoxicity assay. The cytotoxicity of AMP against HeLa cells was determined as previously described 21 .
Viable intracellular bacterial count assay. HeLa Animals. Animal studies were performed on specific-pathogen-free, 6-week-old, female ICR mice (DBL, Eumsung, Korea) weighing 18-20 g. Mice were housed in a room under a 12 h reversed light cycle, humidity of 30-40%, and temperature of 22 ± 1 °C. The experiment protocols were approved by the Chung-Ang University Support Center for Animal Experiments, and all methods were performed in accordance with the guidelines and regulations. 
Hemolysis assay.
